Logo image of DBVT

DBV TECHNOLOGIES SA-SPON ADR (DBVT) Stock Fundamental Analysis

NASDAQ:DBVT - Nasdaq - US23306J2006 - ADR - Currency: USD

9.82  +0.05 (+0.49%)

Fundamental Rating

2

DBVT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. DBVT may be in some trouble as it scores bad on both profitability and health. DBVT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DBVT had negative earnings in the past year.
In the past year DBVT has reported a negative cash flow from operations.
In the past 5 years DBVT always reported negative net income.
DBVT had a negative operating cash flow in each of the past 5 years.
DBVT Yearly Net Income VS EBIT VS OCF VS FCFDBVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -174.12%, DBVT is doing worse than 86.93% of the companies in the same industry.
Looking at the Return On Equity, with a value of -416.74%, DBVT is doing worse than 76.04% of the companies in the same industry.
Industry RankSector Rank
ROA -174.12%
ROE -416.74%
ROIC N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
DBVT Yearly ROA, ROE, ROICDBVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

DBVT has a Gross Margin of 83.62%. This is amongst the best in the industry. DBVT outperforms 87.30% of its industry peers.
DBVT's Gross Margin has declined in the last couple of years.
DBVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
DBVT Yearly Profit, Operating, Gross MarginsDBVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
DBVT has more shares outstanding than it did 1 year ago.
DBVT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, DBVT has a worse debt to assets ratio.
DBVT Yearly Shares OutstandingDBVT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
DBVT Yearly Total Debt VS Total AssetsDBVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

DBVT has an Altman-Z score of -3.75. This is a bad value and indicates that DBVT is not financially healthy and even has some risk of bankruptcy.
DBVT has a Altman-Z score (-3.75) which is in line with its industry peers.
DBVT has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.23, DBVT is doing worse than 70.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z -3.75
ROIC/WACCN/A
WACC7.79%
DBVT Yearly LT Debt VS Equity VS FCFDBVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

DBVT has a Current Ratio of 1.43. This is a normal value and indicates that DBVT is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of DBVT (1.43) is worse than 82.21% of its industry peers.
A Quick Ratio of 1.43 indicates that DBVT should not have too much problems paying its short term obligations.
DBVT's Quick ratio of 1.43 is on the low side compared to the rest of the industry. DBVT is outperformed by 81.85% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.43
DBVT Yearly Current Assets VS Current LiabilitesDBVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

DBVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.66%, which is quite impressive.
The Revenue has grown by 224.69% in the past year. This is a very strong growth!
DBVT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.50% yearly.
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.82%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%26.18%

3.2 Future

Based on estimates for the next years, DBVT will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.40% on average per year.
DBVT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 72.05% yearly.
EPS Next Y-36.93%
EPS Next 2Y-20.09%
EPS Next 3Y26.63%
EPS Next 5Y18.4%
Revenue Next Year-55.09%
Revenue Next 2Y268.93%
Revenue Next 3Y438.04%
Revenue Next 5Y72.05%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DBVT Yearly Revenue VS EstimatesDBVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
DBVT Yearly EPS VS EstimatesDBVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DBVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBVT Price Earnings VS Forward Price EarningsDBVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBVT Per share dataDBVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as DBVT's earnings are expected to grow with 26.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.09%
EPS Next 3Y26.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DBVT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (8/8/2025, 8:00:00 PM)

9.82

+0.05 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-29 2025-07-29/amc
Earnings (Next)N/A N/A
Inst Owners48.3%
Inst Owner Change1.37%
Ins Owners0.06%
Ins Owner Change-0.29%
Market Cap268.55M
Analysts82.5
Price Target11.64 (18.53%)
Short Float %0.06%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.16%
PT rev (3m)-11.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.04%
EPS NY rev (1m)0%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)2.38%
Revenue NY rev (3m)2.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 64.7
P/FCF N/A
P/OCF N/A
P/B 9.81
P/tB 9.82
EV/EBITDA N/A
EPS(TTM)-2.72
EYN/A
EPS(NY)-3.92
Fwd EYN/A
FCF(TTM)-3.86
FCFYN/A
OCF(TTM)-3.77
OCFYN/A
SpS0.15
BVpS1
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -174.12%
ROE -416.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.62%
FCFM N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 317.64%
Cap/Sales 56.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 1.43
Altman-Z -3.75
F-Score1
WACC7.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.42%
Cap/Sales(5y)23.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.82%
EPS Next Y-36.93%
EPS Next 2Y-20.09%
EPS Next 3Y26.63%
EPS Next 5Y18.4%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%26.18%
Revenue Next Year-55.09%
Revenue Next 2Y268.93%
Revenue Next 3Y438.04%
Revenue Next 5Y72.05%
EBIT growth 1Y-52.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.89%
OCF growth 3YN/A
OCF growth 5YN/A